| Literature DB >> 20347302 |
Sherri Young1, Karine Fabio, Christophe Guillon, Pramod Mohanta, Timothy A Halton, Diane E Heck, Robert A Flowers, Jeffrey D Laskin, Ned D Heindel.
Abstract
The design and study of two classes of noncompetitive acetylcholinesterase inhibitors (AChEIs) which also function as NSAID prodrugs are reported. The most potent AChEIs disclosed contain an aromatic alkyl-aryl linker between an NSAID and a lipophilic choline mimic and they inhibit acetylcholinesterase (AChE) in the submicromolar range. These agents have the therapeutic potential to dually target inflammation by releasing an NSAID in vivo and activating the cholinergic anti-inflammatory pathway via cholinergic up-regulation. 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20347302 PMCID: PMC2864113 DOI: 10.1016/j.bmcl.2010.02.102
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823